A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension

Trial Profile

A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Azilsartan medoxomil (Primary) ; Valsartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 12 Sep 2017 Planned End Date changed from 25 Aug 2017 to 9 Oct 2017.
    • 12 Sep 2017 Planned primary completion date changed from 25 Aug 2017 to 9 Oct 2017.
    • 14 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top